Related Experiment Videos
Update on the management of immune thrombocytopenic purpura in children
Michael D Tarantino1, Paula Hb Bolton-Maggs
1Comprehensive Bleeding Disorders Center, Peoria, Illinois 61614, USA. mdtara@hemophilia-ctr-peoria.com
Insights
Current guidelines for childhood immune thrombocytopenic purpura (ITP) are evolving. While anti-D immune globulin is a front-line option, treatment decisions for minimally symptomatic children remain controversial, prompting new clinical tools.
Area of Science:
- Pediatric Hematology
- Immunology
- Clinical Therapeutics
Background:
- Management guidelines for immune thrombocytopenic purpura (ITP) in children have evolved since 1996 and 2003.
- Recent literature continues to refine diagnostic and therapeutic approaches to childhood ITP.
Purpose of the Study:
- To review recent advancements in the diagnosis and treatment of immune thrombocytopenic purpura in children.
- To synthesize current evidence and ongoing debates in pediatric ITP management.
Main Methods:
- Literature review of publications from the past decade.
- Analysis of recent studies on diagnostic approaches and treatment strategies.
- Evaluation of evidence for various therapeutic options, including anti-D immune globulin, rituximab, and splenectomy.
Main Results:
- Diagnostic approaches for childhood ITP remain largely unchanged.
- Anti-D immune globulin is confirmed as a first-line treatment option.
- Rituximab shows promise for persistent disease, and splenectomy offers durable long-term effects.
- Treatment decisions for minimally symptomatic children with severe thrombocytopenia are debated.
Conclusions:
- The optimal management strategy for minimally symptomatic children with severe thrombocytopenia is still under investigation.
- Clinical scoring and quality of life tools are being developed to aid treatment and trial design.
- Adult ITP treatment experiences are informing new therapeutic options for children, particularly those with chronic or severe bleeding.
Purpose Of Review:
Since the publication of management guidelines from the American Society of Hematology (1996) and the British Committee for Standards in Haematology (2003), issues surrounding the diagnosis and treatment of immune thrombocytopenic purpura in children continue to evolve. Reports of the last decade are reviewed here.
Recent Findings:
Few data support a change in the diagnostic approach to childhood immune thrombocytopenic purpura. Recent publications have again challenged the need to treat minimally symptomatic children with severely low platelet counts and confirmed that anti-D immune globulin is a front-line treatment option. The management of chronic disease in children is essentially the same as in acute cases that become persistent or refractory to treatment. During the past 3 years, noncontrolled studies have suggested that rituximab may be useful for persistent disease. Elsewhere, encouraging evidence suggests that the effect of splenectomy for children is durable in the long term.
Summary:
The decision to treat or only observe the minimally symptomatic child with severe thrombocytopenia remains controversial. This ongoing debate has served as a mandate to develop and implement clinical scoring and quality of life tools in treatment and clinical trial design. Meanwhile, experiences with adult cases have introduced new drug treatment options for children, especially those with chronic disease and significant bleeding.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Tonsillitis II: Management